Method of reducing the harmful effects of orally or transdermally delivered nicotine

A tobacco use cessation kit comprising:

• a first tobacco product that comprises nicotine and delivers a collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μg/g;
• a second tobacco product that comprises an amount of nicotine that is less than the first tobacco product and delivers a collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μg/g, wherein said first tobacco product and said second tobacco product are cigarettes;
• and
• a third tobacco product that comprises an amount of nicotine that is less than the amount of nicotine in said second tobacco product and delivers a collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μg/g, wherein said first tobacco product, said second tobacco product, and said third tobacco product are cigarettes and wherein said first tobacco product delivers less than 0.7 mg/g nicotine, said second tobacco product delivers less than 0.4 mg/g nicotine, and said third tobacco product delivers less than 0.5 mg/g nicotine.